摘要 |
<p>The present invention provides a medicinal aerosol suspension formulation for MDI administration, comprising:
a) micronised ² 2 -agonist;
b) micronised corticosteroid;
c) a sub-therapeutic quantity of a moisture-scavenger excipient; and
d) a HFA propellant;
wherein (a), (b) and (c) and their respective relative amounts are selected such that they associate to form floccules having a density substantially the same as that of the HFA propellant.</p> |